Viewing Study NCT00337259



Ignite Creation Date: 2024-05-05 @ 4:52 PM
Last Modification Date: 2024-10-26 @ 9:25 AM
Study NCT ID: NCT00337259
Status: TERMINATED
Last Update Posted: 2016-02-17
First Post: 2006-06-14

Brief Title: Gemcitabine for Marginal Zone Lymphoma
Sponsor: Asan Medical Center
Organization: Asan Medical Center

Study Overview

Official Title: Phase II Study of Gemcitabine in Patients With Advanced Stage Marginal Zone B-cell Lymphoma
Status: TERMINATED
Status Verified Date: 2016-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: poor accrual and response less than expected on interim analysis
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Marginal zone lymphoma one of the indolent lymphoma is believed to be incurable with chemotherapy Thus the investigators need a novel agent for marginal zone lymphoma Gemcitabine has been tried as one of salvage chemotherapy regimen and has been shown to have anti-lymphoma activity To the investigators knowledge there has been no trial of gemcitabine for marginal zone lymphoma Thus the investigators made a plan to investigate the role of gemcitabine in marginal zone lymphoma
Detailed Description: We designed a multi-center phase II trial of gemcitabine for advanced stage marginal zone B-cell lymphoma Marginal zone lymphoma needs novel agent to improve clinical course by chemotherapy Recent trials with new agents for indolent lymphoma shows promising results Gemcitabine is known to have activity to non-Hodgkins lymphoma and has less adverse effects than other new agents With this background gemcitabine will be tried as a single agent for advanced marginal zone lymphoma

Gemcitabine will be administered with 1250mgsqm on days 1 and 8 every 3 weeks Response will be assessed by IWC criteria

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None